EGFR and familial pancreatic carcinoma: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) and has been widely used in EGFR mutant advanced NSCLC patients 36 and advanced pancreatic cancer patients 37.